Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 17

1.

Newly identified events in the RE-LY trial.

Connolly SJ, Ezekowitz MD, Yusuf S, Reilly PA, Wallentin L; Randomized Evaluation of Long-Term Anticoagulation Therapy Investigators.

N Engl J Med. 2010 Nov 4;363(19):1875-6. doi: 10.1056/NEJMc1007378. No abstract available.

2.

Comparison of efficacy and safety of dabigatran, rivaroxaban and apixaban in patients with atrial fibrillation using network meta-analysis.

Harenberg J, Marx S, Diener HC, Lip GY, Marder VJ, Wehling M, Weiss C.

Int Angiol. 2012 Aug;31(4):330-9. Review.

PMID:
22801398
3.

Dabigatran etexilate (Pradaxa)--a new oral anticoagulant.

[No authors listed]

Med Lett Drugs Ther. 2010 Nov 15;52(1351):89-90. Review.

PMID:
21068702
4.

Atrial fibrillation and dabigatran: has the time come to use new anticoagulants?

Escobar C, Barrios V, Jimenez D.

Cardiovasc Ther. 2010 Oct;28(5):295-301. doi: 10.1111/j.1755-5922.2010.00216.x. Epub 2010 Aug 16. Review.

PMID:
20718760
5.

[Preventing stroke by treating atrial fibrillation--new hope with dronedarone and dabigatran?].

Röther J, Laufs U.

Dtsch Med Wochenschr. 2010 Mar;135 Suppl 2:S55-8. doi: 10.1055/s-0030-1249210. Epub 2010 Mar 10. Review. German.

PMID:
20221980
6.

Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: resolving uncertainties in routine practice.

Huisman MV, Lip GY, Diener HC, Brueckmann M, van Ryn J, Clemens A.

Thromb Haemost. 2012 May;107(5):838-47. doi: 10.1160/TH11-10-0718. Epub 2012 Feb 8. Review.

PMID:
22318514
7.

Dabigatran and atrial fibrillation: the alternative to warfarin for selected patients.

[No authors listed]

Prescrire Int. 2012 Feb;21(124):33-6. Review.

PMID:
22413715
8.

Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.

Potpara TS, Polovina MM, Licina MM, Stojanovic RM, Prostran MS, Lip GY.

Adv Ther. 2012 Jun;29(6):491-507. doi: 10.1007/s12325-012-0026-8. Epub 2012 Jun 7. Review.

PMID:
22684583
9.

[New oral anticoagulants for atrial fibrillation: a neurologist's view].

van Dijk EJ, Koudstaal PJ, Roos YB, Brouwers PJ, Kappelle LJ.

Ned Tijdschr Geneeskd. 2012;156(39):A5283. Review. Dutch.

PMID:
23009824
10.

Dabigatran in clinical practice.

Nagarakanti R, Ellis CR.

Clin Ther. 2012 Oct;34(10):2051-60. doi: 10.1016/j.clinthera.2012.09.008. Epub 2012 Sep 29. Review.

PMID:
23031622
11.

An indirect comparison of dabigatran, rivaroxaban and apixaban for atrial fibrillation.

Mantha S, Ansell J.

Thromb Haemost. 2012 Sep;108(3):476-84. doi: 10.1160/TH12-02-0093. Epub 2012 Jun 28. Review.

PMID:
22740145
12.

Antithrombotic treatment of atrial fibrillation: new insights.

Le Heuzey JY.

Thromb Res. 2012 Oct;130 Suppl 1:S59-60. doi: 10.1016/j.thromres.2012.08.277. Review.

PMID:
23026665
13.

Dabigatran etexilate: A novel oral direct thrombin inhibitor.

Blommel ML, Blommel AL.

Am J Health Syst Pharm. 2011 Aug 15;68(16):1506-19. doi: 10.2146/ajhp100348. Review.

PMID:
21817082
14.

Questions and answers on the use of dabigatran and perspectives on the use of other new oral anticoagulants in patients with atrial fibrillation. A consensus document of the Italian Federation of Thrombosis Centers (FCSA).

Pengo V, Crippa L, Falanga A, Finazzi G, Marongiu F, Palareti G, Poli D, Testa S, Tiraferri E, Tosetto A, Tripodi A, Manotti C; Italian Federation of Thrombosis Centers.

Thromb Haemost. 2011 Nov;106(5):868-76. doi: 10.1160/TH11-05-0358. Epub 2011 Sep 22. Review.

PMID:
21946939
15.

Dabigatran etexilate: future directions in anticoagulant treatment.

Schulman S, Reilly PA.

Clin Appl Thromb Hemost. 2009 Sep-Oct;15 Suppl 1:32S-41S. doi: 10.1177/1076029609344199. Epub 2009 Aug 13. Review.

PMID:
19679590
16.
17.

[Prophylaxis of stroke and embolisms in atrial fibrillation--what is new in the guidelines?].

Lewalter T.

MMW Fortschr Med. 2012 Mar 22;154(5):50-2, 54. Review. German. No abstract available.

PMID:
22624265

Supplemental Content

Support Center